.Nature Medication, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) procedure of patients with HER2+ innovative breast cancer as well as energetic or stable mind metastases showed constant intracranial activity and wide spread effectiveness of T-DXd.